Finnerty J P, Holgate S T
Immunopharmacology Group, Sothampton General Hospital, UK.
Eur Respir J. 1993 Sep;6(8):1132-7.
Histamine release has been implicated in the pathogenesis of exercise-induced asthma (EIA), and is believed to be partly mediated by vagal stimulation. Our aim was to determine the relationship between the contributions of vagal stimulation (determined by the use of the muscarinic receptor antagonist, ipratropium bromide) and histamine release (determined by the use of the histamine H1-receptor antagonist terfenadine) in EIA. Ten stable asthmatic subjects with documented EIA took part in a randomized double-blind study. Each undertook four identical treadmill exercise tests, following drug therapy with one of the following: nebulized ipratropium bromide, 0.5 mg, terfenadine, 180 mg, by mouth, both active drugs together, and placebo preparations by mouth and by nebulizer. The mean +/- SEM maximum percentage fall in forced expiratory volume in one second (FEV1) after exercise following placebo therapy was 33.6 +/- 3.8%, which significantly decreased to 27.2 +/- 3.6% after terfenadine, to 21.8 +/- 3.9% after ipratropium bromide, and to 15.1 +/- 4.1% after the combination of both drugs. The addition of ipratropium bromide to terfenadine treatment improved on the protection offered by terfenadine alone. We conclude that both histamine release and vagal stimulation contribute independently and additively to EIA.
组胺释放与运动诱发哮喘(EIA)的发病机制有关,并且据信部分是由迷走神经刺激介导的。我们的目的是确定在EIA中迷走神经刺激(通过使用毒蕈碱受体拮抗剂异丙托溴铵来确定)和组胺释放(通过使用组胺H1受体拮抗剂特非那定来确定)之间的关系。十名有EIA记录的稳定哮喘患者参与了一项随机双盲研究。每个人都进行了四次相同的跑步机运动测试,在接受以下药物治疗之一后进行:雾化吸入0.5毫克异丙托溴铵、口服180毫克特非那定、两种活性药物一起使用以及口服和雾化吸入安慰剂制剂。安慰剂治疗后运动后一秒用力呼气量(FEV1)的平均±SEM最大百分比下降为33.6±3.8%,特非那定治疗后显著降至27.2±3.6%,异丙托溴铵治疗后降至21.8±3.9%,两种药物联合使用后降至15.1±4.1%。在特非那定治疗中添加异丙托溴铵比单独使用特非那定提供的保护有所改善。我们得出结论,组胺释放和迷走神经刺激均独立且相加地促成EIA。